glp 1 polycystic kidney disease The Influence of Non-Pharmacological and Pharmacological Interventions on the Course of Autosomal Dominant GLP-1 agonists in the treatment

A., & Sahebkar, A

In the SOUL trial, published in March 2025 in the New England Journal of Medicine , researchers studied 9,650 participants aged 50 and older with type 2 diabetes and either cardiovascular or kidney disease

GLP-1 plays a key role in the occurrence and development of metabolic diseases such as obesity, nonalcoholic fatty liver disease, and atherosclerosis by regulating lipid metabolism

Yes, it can be

Improvements were seen in pain, bloating, and diarrhea, while constipation and satiety symptoms did not change significantly

While some patients report reduced alcohol interest during semaglutide therapy, the medication is not approved or proven effective for treating alcohol use disorder